谷 poss赤vel uma vacina g那nica auxiliar no controle da tuberculose?

作者：Rodrigues Junior; Jose Maciel; Lima; Karla de Melo; Castelo; Arlete Aparecida Martins Coelho; Martins; Vania Luiza Deperon Bonato; Santos; Sandra Aparecida dos; Faccioli; Lucia Helena; Silva; Celio Lopes

来源：Jornal Brasileiro de Pneumologia, 2004.

DOI：10.1590/S1806-37132004000400013

• tuberculosis [epidemiology]
• vaccines
• dna [therapeutic use]
• heat shock proteins
• auto-immunity.

the dna vaccines currently under pre-clinical and clinical development may prove to be important tools in combating infectious diseases, such as tuberculosis, for which no safe and effective form of prevention has yet been developed. in recent years, several studies have aimed to develop a dna vaccine encoding mycobacterial proteins such as antigen 85 (ag85) and the 65-kda mycobacterial heat shock protein (hsp65). the latter is protective against virulent infection with mycobacterium tuberculosis (including multidrug-resistant strains). the hsp65 dna vaccine, currently under clinical evaluation in brazil for cancer therapy, is able to induce the secretion of th1 cytokines, such as gamma-interferon, associated with disease control. furthermore, this vaccine stimulates cytotoxic cd8 and cd4 t-cell clones that can be characterized as memory cells, which are responsible for effective and long-lasting immunity against tuberculosis. when used as a therapeutic agent in inoculated mice, the hsp65 dna vaccine promotes changes in the immunity profile, triggering the secretion of th1 cytokines and establishing a favorable environment for the elimination of bacilli. the results also demonstrate that the route of administration, as well as the formulation in which the vaccine is administered, fundamentally influence the pattern and duration of the immune response induced. taking all currently available data into account, we can conclude that a dna vaccine against tuberculosis could contribute significantly to the control of the disease.